Profile data is unavailable for this security.
About the company
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
- Revenue in SEK (TTM)563.33m
- Net income in SEK-212.52m
- Incorporated1996
- Employees227.00
- LocationBoule Diagnostics ABDomnarsvgatan 4SPANGA 163 53SwedenSWE
- Phone+46 87447700
- Fax+46 87447720
- Websitehttps://www.boule.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcoma AB | 171.33m | 12.98m | 141.74m | 32.00 | 10.92 | 2.40 | 6.92 | 0.8273 | 0.9844 | 0.9844 | 12.99 | 4.48 | 1.87 | 3.48 | 7.87 | 5,526,807.00 | 14.18 | 1.12 | 24.21 | 2.01 | 38.29 | 37.66 | 7.58 | 0.7568 | 1.24 | 25.82 | 0.00 | 0.00 | 30.36 | 6.41 | 34.81 | -- | 22.75 | -- |
| Bactiquant A/S | 13.92m | -22.44m | 152.88m | -- | -- | 14.45 | -- | 10.98 | -0.6558 | -0.6558 | 0.4064 | 0.2906 | 0.5101 | 2.94 | 5.06 | -- | -82.23 | -41.26 | -92.65 | -47.16 | -24.34 | 12.89 | -161.20 | -71.77 | 2.73 | -9.48 | 0.5326 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| Nanexa AB | 26.66m | -64.42m | 160.80m | 16.00 | -- | 1.95 | -- | 6.03 | -0.6156 | -0.6156 | 0.2087 | 0.6084 | 0.2333 | -25.66 | 3.49 | 1,403,211.00 | -56.37 | -40.77 | -74.68 | -48.77 | 113.04 | 77.27 | -241.64 | -532.26 | 1.90 | -- | 0.0149 | -- | 925.42 | 147.00 | -30.44 | -- | 39.10 | -- |
| Q linea AB | 2.27m | -218.33m | 175.28m | 97.00 | -- | 6.83 | -- | 77.35 | -1.87 | -1.87 | 0.0194 | 0.219 | 0.0107 | 0.1224 | 3.01 | 17,842.52 | -103.05 | -59.66 | -149.74 | -66.14 | -124.10 | -378.58 | -9,635.17 | -4,046.97 | 0.4141 | -- | 0.7825 | -- | -65.28 | 33.02 | 14.64 | -- | 41.94 | -- |
| Micropos Medical AB (publ) | 2.55m | -23.03m | 213.67m | 9.00 | -- | 14.53 | -- | 83.93 | -0.1536 | -0.1536 | 0.017 | 0.0964 | 0.1238 | 0.1034 | 2.09 | 318,247.50 | -112.02 | -64.24 | -154.79 | -82.27 | 82.20 | 114.76 | -904.59 | -767.57 | 2.73 | -- | 0.0249 | -- | 50.23 | 5.94 | -26.57 | -- | -- | -- |
| INIFY Laboratories AB | 9.42m | -51.85m | 240.24m | 26.00 | -- | 5.04 | -- | 25.49 | -1.17 | -1.17 | 0.212 | 1.07 | 0.1164 | 2.16 | 1.83 | -- | -64.03 | -- | -64.03 | -- | 84.45 | -- | -550.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Scandinavian Medical Solutions A/S | 305.97m | 8.32m | 264.14m | 25.00 | 31.58 | 2.21 | 14.07 | 0.8633 | 0.1963 | 0.1963 | 7.22 | 2.81 | 1.38 | 1.89 | 11.35 | -- | 3.75 | -- | 6.15 | -- | 24.48 | -- | 2.72 | -- | 0.4307 | 5.54 | 0.3473 | -- | 72.98 | -- | 7.49 | -- | -- | -- |
| Boule Diagnostics AB | 563.33m | -212.52m | 283.48m | 227.00 | -- | 1.11 | -- | 0.5032 | -5.48 | -5.48 | 14.17 | 6.56 | 0.8515 | 4.58 | 3.95 | 2,470,741.00 | -32.14 | 1.67 | -48.62 | 2.40 | 45.14 | 43.50 | -37.74 | 2.04 | 0.7686 | -24.41 | 0.4116 | 42.24 | 4.24 | 6.13 | 96.24 | -9.45 | -9.74 | -- |
| Karolinska Development AB | 1.90m | -5.65m | 301.77m | 8.00 | -- | 0.2473 | -- | 158.57 | -0.0209 | -0.0209 | 0.007 | 4.56 | 0.0015 | -- | 1.38 | 237,875.00 | -0.4536 | 3.37 | -0.4578 | 3.83 | -- | -- | -296.85 | 1,466.36 | -- | -- | 0.0021 | 0.00 | -12.43 | -8.10 | 106.11 | -29.31 | -- | -- |
| Ortoma AB | 47.46m | -29.81m | 332.95m | 7.00 | -- | 2.02 | -- | 7.02 | -0.7638 | -0.7638 | 1.26 | 4.65 | 0.2497 | 1.84 | 8.68 | 6,779,500.00 | -15.68 | -10.45 | -17.11 | -11.64 | 69.05 | 339.86 | -62.81 | -175.52 | 3.39 | -- | 0.00 | -- | -- | -- | -38.87 | -- | 14.14 | -- |
| Acarix AB | 6.26m | -70.95m | 351.04m | 9.00 | -- | 4.74 | -- | 56.10 | -0.1168 | -0.1168 | 0.0095 | 0.0697 | 0.0894 | 0.1172 | 2.47 | -- | -101.38 | -66.93 | -123.43 | -77.12 | 88.27 | 79.42 | -1,133.87 | -1,483.68 | 5.21 | -328.98 | 0.00 | -- | 7.20 | 43.55 | -1.11 | -- | -- | -- |
| ContextVision AB | 129.72m | 21.73m | 378.92m | 41.00 | 17.43 | 3.97 | 12.60 | 2.92 | 0.2858 | 0.2858 | 1.71 | 1.26 | 1.13 | 2.36 | 4.82 | 3,299,679.00 | 18.89 | 29.39 | 23.79 | 43.27 | 96.83 | 98.58 | 16.76 | 27.15 | 4.57 | -- | 0.017 | -- | 12.19 | 7.78 | -1.77 | -- | -35.88 | -- |
| BrainCool AB (publ) | 37.48m | -57.58m | 405.43m | 20.00 | -- | 2.64 | -- | 10.82 | -0.2635 | -0.2635 | 0.1695 | 0.6071 | 0.2378 | 2.01 | 3.76 | 1,561,500.00 | -36.54 | -47.14 | -39.83 | -70.16 | -32.65 | -149.77 | -153.65 | -391.45 | 3.64 | -5.86 | 0.00 | -- | 32.06 | 78.35 | -34.34 | -- | -11.63 | -- |
Data as of Nov 12 2024. Currency figures normalised to Boule Diagnostics AB's reporting currency: Swedish Krona SEK
45.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Svolder AB (Investment Management)as of 31 Mar 2024 | 4.29m | 11.05% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 3.43m | 8.84% |
| Tredje AP-fondenas of 31 Mar 2024 | 3.25m | 8.37% |
| Nordea Investment Management ABas of 30 Jun 2024 | 3.07m | 7.90% |
| Andra AP-fondenas of 31 Mar 2024 | 1.37m | 3.53% |
| Aktia Bank Plc (Investment Management)as of 30 Sep 2024 | 992.54k | 2.56% |
| Wahlstedt & Partners ABas of 30 Sep 2024 | 450.00k | 1.16% |
| SEB Investment Management ABas of 30 Sep 2024 | 243.32k | 0.63% |
| Handelsbanken Fonder ABas of 30 Sep 2024 | 213.85k | 0.55% |
| Tiff Advisory Services LLCas of 30 Jun 2024 | 180.98k | 0.47% |
More ▼
Data from 29 Feb 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
